- Result of Annual General Meeting
- Operations Update
- Posting of Annual Report & Notice of AGM
- Final Results
- Total Voting Rights
- Placing to Raise US$4.2 million
- FDA Consents to Phase I Trials of HEMO-CAR-T
- Approval and Issuance of U.S. Conditioning Patent
- Submission of Complete Response to Clinical Hold
- HEMO-CAR-T Process Qualification Run Completed
More ▼
Key statistics
On Monday, Hemogenyx Pharmaceuticals PLC (HEMO:LSE) closed at 1.33, 9.02% above its 52-week low of 1.22, set on Jul 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.30 |
---|---|
High | 1.34 |
Low | 1.30 |
Bid | 1.30 |
Offer | 1.37 |
Previous close | 1.29 |
Average volume | 4.45m |
---|---|
Shares outstanding | 1.34bn |
Free float | 1.20bn |
P/E (TTM) | -- |
Market cap | 17.18m GBP |
EPS (TTM) | -0.0061 GBP |
Data delayed at least 20 minutes, as of Jul 22 2024 16:17 BST.
More ▼